Stock traders buy large volume of call options from Reata Pharmaceuticals (NASDAQ: RETA)
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) saw unusually large options trading on Monday. Stock traders bought 23,732 call options on the stock. This is an increase of 1,617% over the average volume of 1,382 call options.
Separately, Robert W. Baird lowered his price target on Reata Pharmaceuticals from $ 212.00 to $ 110.00 and set an “outperformance” rating on the stock in a research note Monday. They noted that the move was an appraisal call. Five analysts rated the stock with a buy rating. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $ 197.80.
Reata Pharmaceuticals stock traded down $ 29.83 during trading hours on Monday, reaching $ 48.86. The stock had a trading volume of 303,885 shares, compared to its average volume of 363,839. The stock has a market cap of $ 1.78 billion, a price / earnings ratio of -6.18 and a beta of 1.48. Reata Pharmaceuticals has a one-year low of $ 76.34 and a one-year high of $ 153.41. The company’s 50-day simple moving average is $ 96.68 and its 200-day simple moving average is $ 114.47.
Reata Pharmaceuticals (NASDAQ: RETA) last released its results on Monday, November 8. The company reported ($ 1.97) EPS for the quarter, beating the consensus estimate of ($ 2.32) by $ 0.35. Reata Pharmaceuticals recorded a negative return on equity of 81.91% and a negative net margin of 2,020.49%. The company posted revenue of $ 7.40 million in the quarter, compared to a consensus estimate of $ 2.07 million. During the same period last year, the company made earnings per share ($ 1.94). The company’s quarterly revenue increased 428.6% year-over-year. As a group, analysts expect Reata Pharmaceuticals to post -8.27 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently changed their holdings to RETA. Stonehage Fleming Financial Services Holdings Ltd purchased a new position in Reata Pharmaceuticals shares during the second quarter valued at approximately $ 50,000. FourThought Financial LLC increased its position in Reata Pharmaceuticals shares by 58.0% during the third quarter. FourThought Financial LLC now owns 583 shares of the company valued at $ 58,000 after acquiring 214 additional shares in the last quarter. Macquarie Group Ltd. increased its position in Reata Pharmaceuticals shares by 60.1% in the third quarter. Macquarie Group Ltd. now owns 594 shares of the company valued at $ 60,000 after acquiring 223 additional shares in the last quarter. O Shaughnessy Asset Management LLC increased its position in Reata Pharmaceuticals shares by 6,360.0% during the third quarter. O Shaughnessy Asset Management LLC now owns 646 shares of the company valued at $ 65,000 after acquiring an additional 636 shares in the last quarter. Finally, First Mercantile Trust Co. increased its position in Reata Pharmaceuticals shares by 20.6% during the third quarter. First Mercantile Trust Co. now owns 721 shares of the company valued at $ 73,000 after acquiring 123 additional shares in the last quarter. Institutional investors hold 74.04% of the shares of the company.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the identification, development and commercialization of pharmaceutical products. Its product candidates are methyl bardoxolone and omaveloxolone, which activate the Nrf2 transcription factor to restore mitochondrial function, reduce oxidative stress and resolve inflammation.
Further reading: quick report
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Reata Pharmaceuticals now?
Before you consider Reata Pharmaceuticals, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold … and Reata Pharmaceuticals was not on the list.
While Reata Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here